Please note these changes from the Pharmacy and Therapeutics Committee meeting on Sept. 5.
Sodium zirconium cyclosilicate (Lokelma) was added to formulary as an alternative potassium binder to sodium polystyrene sulfonate.
Combination insulins (i.e. 70/30, 75/25 or 50/50) are being removed from the formulary due to increased risk of hypoglycemia due to combination insulins.
The timelines for roll out of Lokelma and removal of combination insulins are pending.
If you have any questions about these or other P&T related questions, please contact Matt Tanner (503-814-9960 or matthew.tanner@salemhealth.org).